2025 Volume 58 Issue 4 Pages 208-214
There has been a rise in the use of the tunneled cuffed catheter (TCC) due to increases in the aging population undergoing hemodialysis as well as duration of hemodialysis. However, there are limited reports on its long‒term results in Japan. Therefore, we evaluated the results of first implantation of TCC (CentrosFLO) in 65 patients from October 2020 to April 2024. They comprised 40 male and 25 female patients with a mean age of 77 (57‒90) years, involving 31 cases of Bridge Use (BU) for temporary implantation and 34 cases of Permanent Use (PU) for other purposes, all implanted via the right internal jugular vein. The local infection rates were 0.18 and 0.06 for bloodstream infections per 1,000 catheter days, respectively. Interestingly, the patency rate was 100％ at 2 years. Survival rates were 79 and 72％ at 1 and 2 years for BU and 41 and 25％ at 1 and 2 years for PU, respectively. Thus, with TCC (CentrosFLO), although its use involves some associated complications, the long‒term patency results are satisfactory, and so it can be applied without any apprehensions.
